Multiple Myeloma: The CAR T-cell Therapy Landscape Available to Purchase

BCMA-targeting chimeric antigen receptor T cells increasingly look like a potent option for multiple myeloma. Across several candidates spotlighted during the 2019 American Society of Hematology Annual Meeting, high response rates were seen in patients whose disease was refractory to multiple standard therapies.